These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
94 related articles for article (PubMed ID: 24165827)
1. Selective apoptosis of multiple myeloma cells in primary samples induced by arsenic trioxide. Reberšek K; Žontar DM; Černelč P; Podgornik H Hematology; 2014 Sep; 19(6):346-51. PubMed ID: 24165827 [TBL] [Abstract][Full Text] [Related]
2. Proteomic and functional analyses reveal a dual molecular mechanism underlying arsenic-induced apoptosis in human multiple myeloma cells. Ge F; Lu XP; Zeng HL; He QY; Xiong S; Jin L; He QY J Proteome Res; 2009 Jun; 8(6):3006-19. PubMed ID: 19364129 [TBL] [Abstract][Full Text] [Related]
3. Sustained activation of c-jun-N-terminal kinase plays a critical role in arsenic trioxide-induced cell apoptosis in multiple myeloma cell lines. Kajiguchi T; Yamamoto K; Iida S; Ueda R; Emi N; Naoe T Cancer Sci; 2006 Jun; 97(6):540-5. PubMed ID: 16734734 [TBL] [Abstract][Full Text] [Related]
4. Realgar nanoparticles versus ATO arsenic compounds induce in vitro and in vivo activity against multiple myeloma. Cholujova D; Bujnakova Z; Dutkova E; Hideshima T; Groen RW; Mitsiades CS; Richardson PG; Dorfman DM; Balaz P; Anderson KC; Jakubikova J Br J Haematol; 2017 Dec; 179(5):756-771. PubMed ID: 29048129 [TBL] [Abstract][Full Text] [Related]
5. Arsenic trioxide-mediated growth inhibition of myeloma cells is associated with an extrinsic or intrinsic signaling pathway through activation of TRAIL or TRAIL receptor 2. Wu X; Shi J; Wu Y; Tao Y; Hou J; Meng X; Hu X; Han Y; Jiang W; Tang S; Zangari M; Tricot G; Zhan F Cancer Biol Ther; 2010 Dec; 10(11):1201-14. PubMed ID: 20953137 [TBL] [Abstract][Full Text] [Related]
6. P38 MAPK inhibition enhancing ATO-induced cytotoxicity against multiple myeloma cells. Wen J; Cheng HY; Feng Y; Rice L; Liu S; Mo A; Huang J; Zu Y; Ballon DJ; Chang CC Br J Haematol; 2008 Jan; 140(2):169-80. PubMed ID: 18173754 [TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of arsenic trioxide on retinoblastoma: cell differentiation and apoptosis depending on arsenic trioxide concentration. Kim JH; Kim JH; Yu YS; Kim DH; Kim CJ; Kim KW Invest Ophthalmol Vis Sci; 2009 Apr; 50(4):1819-23. PubMed ID: 19060284 [TBL] [Abstract][Full Text] [Related]
8. Molecular targets of arsenic trioxide in malignant cells. Miller WH Oncologist; 2002; 7 Suppl 1():14-9. PubMed ID: 11961205 [TBL] [Abstract][Full Text] [Related]
9. Effects of arsenic trioxide alone and in combination with bortezomib in multiple myeloma RPMI 8266 cells. Elmahi AY; Niu C; Li W; Li D; Wang GJ; Hao SS; Cui JW Asian Pac J Cancer Prev; 2013; 14(11):6469-73. PubMed ID: 24377552 [TBL] [Abstract][Full Text] [Related]
10. Arsenic trioxide is effective in the treatment of multiple myeloma in SCID mice. Rousselot P; Larghero J; Labaume S; Poupon J; Chopin M; Dosquet C; Marolleau JP; Janin A; Brouet JC; Fermand JP Eur J Haematol; 2004 Mar; 72(3):166-71. PubMed ID: 14962234 [TBL] [Abstract][Full Text] [Related]
11. Reactive oxygen species are not required for an arsenic trioxide-induced antioxidant response or apoptosis. Morales AA; Gutman D; Cejas PJ; Lee KP; Boise LH J Biol Chem; 2009 May; 284(19):12886-95. PubMed ID: 19279006 [TBL] [Abstract][Full Text] [Related]
12. Arsenic trioxide inhibits the growth of Calu-6 cells via inducing a G2 arrest of the cell cycle and apoptosis accompanied with the depletion of GSH. Han YH; Kim SZ; Kim SH; Park WH Cancer Lett; 2008 Oct; 270(1):40-55. PubMed ID: 18539383 [TBL] [Abstract][Full Text] [Related]
13. Effect of arsenic trioxide on uveal melanoma cell proliferation in vitro. Wang C; Li B; Zhang H; Shi G; Li W; Jonas JB Ophthalmic Res; 2007; 39(6):302-7. PubMed ID: 17957129 [TBL] [Abstract][Full Text] [Related]
14. Realgar (As4S4) nanoparticles and arsenic trioxide (As2O3) induced autophagy and apoptosis in human melanoma cells in vitro. Pastorek M; Gronesova P; Cholujova D; Hunakova L; Bujnakova Z; Balaz P; Duraj J; Lee TC; Sedlak J Neoplasma; 2014; 61(6):700-9. PubMed ID: 25150315 [TBL] [Abstract][Full Text] [Related]
15. Changes in gene expression profiles of multiple myeloma cells induced by arsenic trioxide (ATO): possible mechanisms to explain ATO resistance in vivo. Zhou P; Kalakonda N; Comenzo RL Br J Haematol; 2005 Mar; 128(5):636-44. PubMed ID: 15725085 [TBL] [Abstract][Full Text] [Related]
16. Targeting MEK/MAPK signal transduction module potentiates ATO-induced apoptosis in multiple myeloma cells through multiple signaling pathways. Lunghi P; Giuliani N; Mazzera L; Lombardi G; Ricca M; Corradi A; Cantoni AM; Salvatore L; Riccioni R; Costanzo A; Testa U; Levrero M; Rizzoli V; Bonati A Blood; 2008 Sep; 112(6):2450-62. PubMed ID: 18583568 [TBL] [Abstract][Full Text] [Related]
17. Arsenic trioxide induces programmed cell death through stimulation of ER stress and inhibition of the ubiquitin-proteasome system in human sarcoma cells. Chiu HW; Tseng YC; Hsu YH; Lin YF; Foo NP; Guo HR; Wang YJ Cancer Lett; 2015 Jan; 356(2 Pt B):762-72. PubMed ID: 25449439 [TBL] [Abstract][Full Text] [Related]
18. Arsenic trioxide induces de novo protein synthesis of annexin-1 in neutrophils: association with a heat shock-like response and not apoptosis. Binet F; Chiasson S; Girard D Br J Haematol; 2008 Feb; 140(4):454-63. PubMed ID: 18081892 [TBL] [Abstract][Full Text] [Related]
19. Alterations in glutathione levels and apoptotic regulators are associated with acquisition of arsenic trioxide resistance in multiple myeloma. Matulis SM; Morales AA; Yehiayan L; Lee KP; Cai Y; Boise LH PLoS One; 2012; 7(12):e52662. PubMed ID: 23285138 [TBL] [Abstract][Full Text] [Related]
20. Aquaporin 9, a promising predictor for the cytocidal effects of arsenic trioxide in acute promyelocytic leukemia cell lines and primary blasts. Iriyama N; Yuan B; Yoshino Y; Hatta Y; Horikoshi A; Aizawa S; Takeuchi J; Toyoda H Oncol Rep; 2013 Jun; 29(6):2362-8. PubMed ID: 23563754 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]